PYPD Polypid

PolyPid to Participate in Upcoming Investor Conferences

PolyPid to Participate in Upcoming Investor Conferences

PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:

Aegis Capital Corp. Virtual Conference

Presentation Date: Wednesday, May 3, 2023

Presentation Time: 10:30 AM Eastern Time

Sidoti & Company Micro-Cap Virtual Conference

Presentation Date: Thursday, May 11, 2023

Presentation Time: 9:15 AM Eastern Time

JMP Securities Life Sciences Conference in New York City

Fire Side Chat Date: Monday, May 15, 2023

Fire Side Chat Time: 2:30 PM Eastern Time

The PolyPid management team will participate in one-on-one investor meetings during these events. Investors interested in meeting with the Company around the conferences should contact their Aegis Capital, Sidoti, or JMP Securities representative.

About PolyPid

 (Nasdaq: ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit  and follow us on  and .

Contacts:

PolyPid Ltd. 

Ori Warshavsky

COO – US

908-858-5995

Investors:

Brian Ritchie

LifeSci Advisors

212-915-2578



EN
24/04/2023

Underlying

PYPDPolypid

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026  U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it has initiated a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administra...

March 31, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Ap...

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration (FDA) has granted a small busin...

March 17, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Announces Participation in Upcoming Investor Conferences PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026. Citizens 2026 Life Sciences Conference Date: March 10, 2026 at 1:40 pm ETLocation: Eden Roc Miami Beach, Miami Beach, FLFormat: Fireside chatWebca...

February 25, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-...

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiv...

February 11, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Report Fourth Quarter 2025 Financial Results and Operationa...

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on b...

January 28, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch